Skip to main content

Advertisement

Table 2 Overall response rate

From: A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer

n (%) Overall Neoadjuvant/adjuvant chemotherapy Subtype Visceral metastasis Disease free interval
Yes No With A/T W/O A/T Luminal TN Yes No <2 yr ≥2 yr W/O Op.
Patients 35 (100) 15 (42.9) 20 (57.1) 10 (28.6) 25 (71.4) 28 (80.0) 7 (20.0) 23 (65.7) 12 (34.3) 7 (20.0) 14 (40.0) 14 (40.0)
CR 2 (5.7) 1 (6.7) 1 (5.0) 0 (0.0) 2 (8.0) 2 (7.1) 0 (0.0) 1 (4.3) 1 (8.3) 0 (0.0) 1 (7.1) 1 (7.1)
PR 17 (48.6) 4 (26.7) 13 (65.0) 3 (30.0) 14 (56.0) 13 (46.4) 4 (57.1) 10 (43.5) 7 (58.3) 3 (42.9) 5 (35.7) 9 (64.3)
SD ≥ 24 w 3 (8.6) 2 (13.3) 2 (10.0) 1 (10.0) 3 (12.0) 3 (10.7) 1 (14.3) 3 (13.0) 1 (8.3) 2 (28.6) 1 (7.1) 1 (7.1)
SD < 24 w 8 (22.9) 5 (33.3) 2 (10.0) 4 (40.0) 3 (12.0) 5 (17.9) 2 (28.6) 4 (17.4) 3 (25.0) 1 (14.3) 5 (35.7) 1 (7.1)
PD 2 (5.7) 1 (6.7) 1 (5.0) 0 (0.0) 2 (8.0) 2 (7.1) 0 (0.0) 2 (8.7) 0 (0.0) 0 (0.0) 1 (7.1) 1 (7.1)
NE 3 (8.6) 2 (13.3) 1 (5.0) 2 (20.0) 1 (4.0) 3 (10.7) 0 (0.0) 3 (13.0) 0 (0.0) 1 (14.3) 1 (7.1) 1 (7.1)
ORR 19 (54.3) 5 (33.3) 14 (70.0) 3 (30.0) 16 (64.0) 15 (53.6) 4 (57.1) 11 (47.8) 8 (66.7) 3 (42.9) 6 (42.9) 10 (71.4)
CBR 22 (62.9) 7 (46.7) 16 (80.0) 4 (40.0) 19 (76.0) 18 (64.3) 5 (71.4) 14 (60.9) 9 (75.0) 5 (71.4) 7 (50.0) 11 (78.6)
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR overall response rate, CBR clinical benefit rate, A/T anthracycline- or taxane-based regimens, W/O without, TN triple negative, yr years, Op operation